Manfred Mieskes

Siemens Healthineers expands medical imaging portfolio through €200M Novartis Radiopharmaceuticals deal. Siemens Healthineers is expanding its imaging equipment business with the acquisition of Novartis' radiopharmaceuticals division. The deal, valued at €200 million, is expected to close by the end of the year. Novartis, which acquired the nuclear medicine pharmaceutical provider Advanced Accelerator Applications in 2017, has been offering PET, SPECT, and therapy diagnoses and treatments for oncology, neurology, cardiology and inflammatory diseases. PET scans, while more expensive than MRI, are becoming a valuable tool for diagnosing solid tumors, tracking cancer spread and monitoring patient response to treatment. Siemens Healthineers aims to strengthen its position in the medical imaging market. Novartis acquired AAA for $3.9 billion to gain access to radiopharmaceutical medicine. Representing a promising new frontier in cancer treatment. The drugs are designed to deliver targeted radiotherapy, killing cancerous cells while minimizing damage to healthy tissue. Lutathera which is approved for the use of neuroendocrine tumors is expected to generate $704m in sales this year. Thanks to The Financial Times for the resources: Oliver Barnes, US Pharmaceutical & Biotech Correspondent, Patricia Nilsson, Frankfurt Correspondent Link to the article: https://lnkd.in/ekZx-sYz #SiemensHealthineers #Novartis #Oncology #NuclearMedicine #RadioPharmaceuticals #Cancer #PETScans #MRI #Tumors

10

Expert Insight Into von Hippel-Lindau (VHL) Disease: From Symptoms and Diagnosis to Cutting-Edge Therapies and Adverse Event Management | #MedEd #cme #VHLdisease | https://bit.ly/3OT0hnT

2

Have you read the latest Industry Spotlight article published by #OncologyNetwork? Click on the link via #OncologyNetwork*: https://bit.ly/EPIC-6mo OncoBeta announces recently-published results of the Rostock clinical study plus promising interim results from the EPIC-Skin multicentre study. You'll need to be a registered healthcare professional to gain access. #OncoBeta #Rhenium188 #TreatingNMSC #SkinCancer #NonMelanomaSkinCancer #BCC #SCC #SkinCancerTreatment #Painless #NonInvasive #SingleSession #Aesthetic #EpidermalRadioisotopeTherapy #NuclearMedicine #Dermatology #Personalised #Precision #Rostock #EPIC #EPICSkin #ClinicalStudy

60

On this World Lung Day, we would like to emphasize the importance of Krebs von den Lungen-6 (#KL-6) as a key biomarker for interstitial pneumonia. KL-6, a high molecular weight glycoprotein, is a reliable serum biomarker for interstitial lung diseases (ILD). It plays a key role in diagnosis, monitoring disease activity, evaluating treatment response, and predicting clinical outcomes. Due to the complexity of ILD, patients are frequently misdiagnosed, which could lead to delays in appropriate management #WorldLungDay #Lung #laboratory #laboratoryequipment #diagnosis

27

🧬Update from #ESMO24 - BRAF-altered NSCLC 🧬 Dr Federico Cappuzzo & David Planchard joined us at ESMO 2024 to share their insights into new non-small cell lung cancer data presented at the congress. 📺 Watch the video to get their key takeaways and hear how they think these developments could impact clinical practice 👇 The experts review data from several key trials: ➡️ Updated efficacy and safety from the phase 2 PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant mNSCLC. Riely G, et al. (Abstract LBA56) ➡️ Encorafenib plus binimetinib in patients with previously untreated BRAF V600E-mutant advanced NSCLC: an open-label, multicenter phase 2 trial (IFCT-1904 ENCO-BRAF). Planchard D, et al. (Abstract 1259MO) ➡️ First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E-mutant metastatic NSCLC. Di Federico A, et al. (Abstract 1299P) ➡️ Phase 2 trial of vemurafenib and cobimetinib in BRAF V600-mutated solid tumours and first-Line NSCLC: Australian Molecular Screening and Therapeutics (MoST) Substudy 12 Lin F, et al. (Abstract 623P) Supported by an Independent Education Grant from Pierre Fabre. This content is not intended for HCPs within the UK. #MedicalEducation #Oncology

31

The new treatment concepts in pancreatic cancer in the CECOG masterclass - Eric Van Cutsem Christoph Zielinski https://lnkd.in/eZkMt-dy #OncoDaily #Oncology #Cancer #Health #Medicine #PancreaticCancer #CancerTreatment

21

🔬 Insights from ESMO - European Society for Medical Oncology24 on Neoadjuvant Immuno-Oncology 🔬 Edgardo S. Santos, MD, FACP, FASCO, Vice President of the Florida Society of Clinical Oncology, shared key takeaways from a recent session on Immuno-Oncology (IO) at ESMO24 https://lnkd.in/eiKUdyFb #ESMO24 #OncoDaily #Oncology #Cancer #Health #Medicine

26

Critics of The CMS’s IOTA Model (https://lnkd.in/eHS-xFg3) are easy to find. But could they be missing the point? What if this is but the next step toward a future where ESKD patients receive transplants sooner? Who would argue with a future where patients get transplanted sooner, with fewer months of dialysis? CMS aims to boost kidney transplantation through a six-year “sort-of mandatory” program starting in 2025, featuring incentives and enhanced reporting requirements for transplant centers. Whether it will effectively address this critical need in US healthcare is debatable. While CMS believes in its potential, some kidney health experts argue that the model may be too weak and complex to compel transplant centers to improve.   **Key Considerations** 1. Living Kidney Donation is the path to growth. The IOTA Model emphasizes living kidney donation (LKD), referencing it 110 times in the 158-page proposed rule (https://lnkd.in/e66uS_nb). While there are no specific incentives for increasing LKD, CMS is likely to pursue more regulations in this area through amendments to the IOTA Model. 2. Bigger sticks on the way? The IOTA Model follows CMS's recent focus on kidney care innovation. While the proposed incentives are weak, they could lay the groundwork for future requirements, making kidney transplants a pilot for broader reforms in organ transplantation, using both larger carrots and more meaningful sticks.   **Conclusions** 1. There is little question that transplant centers will soon be mandated to prepare for the IOTA Model in 2025. 2. The reputational risk of not meeting the IOTA Model's yearly score thresholds will likely outweigh the financial implications of incentives or penalties at the outset. 3. Centers that fail to analyze their processes risk falling behind their peers in the published metrics resulting from implementing this regulation. We welcome your thoughts on this topic, as we focus on helping transplant centers enhance their LKD programs for better throughput, cost management and equity. #transplant #kidneytransplant #livingdonation

2

🫁 Tomorrow is World Lung Cancer Day 🫁   "The proportion of non-smoking-related lung cancers is constantly increasing, currently between 15-20% of all lung cancers in Europe," explains Torsten Blum.   IDERHA member Torsten Blum is a pulmonologist and thoracic oncologist. For World Lung Cancer Day he shared his insights on IDERHA with researcher Rebecca C. Graebig-Rancourt, Ph.D.   Read more here: https://lnkd.in/e3KkHpHa   #WorldLungCancerDay #lungcancer #patientengagement #datascience #ai #machinelearning #datainfrastructure #dataaccess #healthdata #healthpolicymaking #hta #ehds #realworldevidence #realworlddata

25